BIO:NYE-Bio-Rad Laboratories Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 503.49

Change

-10.87 (-2.11)%

Market Cap

USD 15.11B

Volume

0.21M

Avg Analyst Target

USD 750.00 (+48.96%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Bio-Rad Laboratories Inc (BIO) Stock Analysis:
Based on the Bio-Rad Laboratories Inc stock forecasts from 2 analysts, the average analyst target price for Bio-Rad Laboratories Inc is USD 750.00 over the next 12 months. Bio-Rad Laboratories Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bio-Rad Laboratories Inc is Bullish , which is based on 8 positive signals and 2 negative signals. At the last closing, Bio-Rad Laboratories Inc’s stock price was USD 503.49. Bio-Rad Laboratories Inc’s stock price has changed by +5.95% over the past week, -7.16% over the past month and -14.39% over the last year.

About

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment dev ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

-1.80 (-1.57%)

USD200.55B 26.59 15.49
MDT Medtronic plc

-2.69 (-2.53%)

USD142.55B 29.28 17.05
SYK Stryker Corporation

-6.92 (-2.89%)

USD90.43B 45.47 27.69
EW Edwards Lifesciences Corporati..

-3.98 (-4.09%)

USD60.55B 40.08 30.72
BSX Boston Scientific Corporation

-1.09 (-2.64%)

USD59.07B 77.96 25.48
ZBH Zimmer Biomet Holdings Inc

-2.93 (-2.45%)

USD24.59B 61.37 19.18
STE STERIS plc

-2.52 (-1.14%)

USD22.19B 74.95 58.23
PHG Koninklijke Philips N.V

-0.54 (-2.14%)

USD21.50B 6.80 48.48
BIO-B Bio-Rad Laboratories Inc

N/A

USD14.97B 3.59 2.64
SNN Smith & Nephew plc

-0.83 (-2.57%)

USD13.84B 26.57 12.25

ETFs Containing BIO

Symbol Name Weight Mer Price(Change) Market Cap
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

-0.69 (-1.85%)

USD0.02B
FXH First Trust Health Care A.. 0.00 % 0.61 %

-2.99 (-2.77%)

USD1.41B
DRDR:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-4.88 (-0.86%)

USD1.34B
HEAL:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-0.13 (-1.77%)

USD1.34B
NSGE:CA NBI Sustainable Global Eq.. 0.00 % 0.74 %

N/A

USD0.44B
GERM ETF Managers Trust - ETFM.. 0.00 % 0.68 %

-0.55 (-2.34%)

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.79 %

N/A

N/A
PFUT Putnam Sustainable Future.. 0.00 % 0.64 %

-0.72 (-4.10%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.36% 31% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.36% 31% F 13% F
Trailing 12 Months  
Capital Gain -14.46% 70% C- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.46% 70% C- 35% F
Trailing 5 Years  
Capital Gain 129.67% 82% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 129.67% 76% C 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 31.11% 89% B+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.11% 85% B 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 23.53% 63% D 49% F
Risk Adjusted Return 132.23% 85% B 98% A+
Market Capitalization 15.11B 72% C- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.61 95% A 94% A
Price/Book Ratio 1.48 83% B 53% F
Price / Cash Flow Ratio 23.01 38% F 15% F
EV/EBITDA 2.64 88% B+ 89% B+
Management Effectiveness  
Return on Equity -0.97% 41% F 21% F
Return on Invested Capital -5.96% 37% F 13% F
Return on Assets 2.64% 57% F 51% F
Debt to Equity Ratio 0.08% 96% A 94% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.37 86% B 63% D
Short Percent 1.56% 61% D- 70% C-
Beta 0.91 57% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector